Business
Cardax Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease
Cardax Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease.
About this update from Cardax Inc
[{"type":"text","content":"\n\n\n\nCardax Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prnsbls{\nBORDER-LEFT:black 1pt solid\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prnsbbs{\nBORDER-BOTTOM:black 1pt solid\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prnrbrs{\nBORDER-RIGHT:black 1pt solid\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbts{\nBORDER-TOP:black 1pt solid\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n\n\n\n\n\n\nCardax Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease\nCardax seeking strategic collaborations to further develop astaxanthin for COVID-19\nPR Newswire\nHONOLULU, March 20, 2020\n\n\n\nHONOLULU, March 20, 2020 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) today released a white paper outlining the potential role of astaxanthin in the treatment of coronavirus disease and is seeking strategic collaborations to further develop astaxanthin for COVID-19. The paper focuses on the scientific rationale of boosting the immune system and reducing the extreme inflammatory response that may lead to severe respiratory complications in subjects with COVID-19, the disease caused by the novel coronavirus (SARS-CoV-2). The paper is entitled \"Astaxanthin: A safe, natural, and multi-faceted anti-inflammatory for maintaining lung health and possibly minimizing SARS-CoV-2 effects\" and can be found at www.cardaxpharma.com/COVID-19. The paper was authored by Timothy J. King, Ph.D., M.S., Vice President, Research, Cardax, Inc. Astaxanthin is the exceptionally safe anti-inflammatory delivered by Cardax's lead pharmaceutical candidate, CDX-101, a proprietary astaxanthin prodrug. \nHighlights:\nScientific Rationale: Immune Response, Inflammation, and COVID-19. The novel coronavirus (SARS-CoV-2) infection can induce COVID-19, an extreme immune response characterized by the overproduction of immune cells and the uncontrolled release of pro-inflammatory cytokines. Exceedingly high levels of the cytoki...